Journal
CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 78, Issue 5, Pages 1861-1871Publisher
SPRINGER BASEL AG
DOI: 10.1007/s00018-020-03676-8
Keywords
MicroRNA; Small-molecule inhibitor; Small-molecule degrader; Drug development; Cancer therapy
Categories
Ask authors/readers for more resources
miRNAs, previously considered undruggable, have recently been shown to be targetable with small molecules such as SMIs and SMDs, which inhibit their biogenesis or induce degradation. These small molecules demonstrate high potency and specificity in miRNA inhibition, providing new opportunities for therapeutic development towards previously considered undruggable targets.
As a naturally occurring class of gene regulators, microRNAs (miRNAs) have attracted much attention as promising targets for therapeutic development. However, RNAs including miRNAs have long been considered undruggable, and most efforts have been devoted to using synthetic oligonucleotides to regulate miRNAs. Encouragingly, recent findings have revealed that miRNAs can also be drugged with small molecules that directly target miRNAs. In this review paper, we give a summary of recently emerged small-molecule inhibitors (SMIs) and small-molecule degraders (SMDs) for miRNAs. SMIs are small molecules that directly bind to miRNAs to inhibit their biogenesis, and SMDs are bifunctional small molecules that upon binding to miRNAs induce miRNA degradation. Strategies for discovering SMIs and developing SMDs were summarized. Applications of SMIs and SMDs in miRNA inhibition and cancer therapy were also introduced. Overall, SMIs and SMDs introduced here have high potency and specificity in miRNA inhibition. We envision that these small molecules will pave the way for developing novel therapeutics toward miRNAs that were previously considered undruggable.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available